Results 41 to 50 of about 358,718 (162)

Exploring tear fluid biomarkers and the ocular surface in thyroid eye disease

Acta Ophthalmologica, Volume 104, Issue 1, Page e28-e38, February 2026.
Abstract Purpose To examine ocular surface changes and inflammatory tear fluid biomarkers in patients with thyroid eye disease (TED). Methods We included 106 Graves' disease (GD) patients (36 without TED, 32 with active and 38 with inactive TED) and 106 age‐ and sex‐matched healthy subjects for ophthalmological evaluation, including ocular surface ...
Mikael Thomassen Neset, Roy Miodini Nilsen, Kristian Løvås, Kathrine Halsøy, Håkon Reikvam, Ann‐Elin Meling Stokland, Grethe Åstrøm Ueland, Anette S. B. Wolff, Hans Christian D. Aass, Sjur Reppe, Eystein Sverre Husebye, Eyvind Rødahl, Tor Paaske Utheim, Hans Olav Ueland   +13 more
wiley   +1 more source

TSHR‐Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition

Advanced Science, Volume 13, Issue 4, 19 January 2026.
This study presents YC3, a novel inhibitory TSHR‐targeting aptamer, as a promising therapeutic for Graves' ophthalmopathy (GO). YC3 suppresses pathological phenotypes in human orbital fibroblasts and improves outcomes in GO mice by binding to a previously unidentified allosteric site on TSHR, demonstrating the potential of aptamers in advancing ...
Yanchen Zhang, Ende Wu, Weibin Liu, Ling Zeng, Neng Ling, Hongmei Wang, Zhixing Li, Shuang Yao, Tonghe Pan, Xuanwen Li, Yate Huang, Xiaojing Li, Yunhai Tu, Wentao Yan, Jianzhang Wu, Mao Ye, Wencan Wu   +16 more
wiley   +1 more source

A Pruritic Predicament: An Unusual Presentation of Graves’ Disease Complicated by Pregnancy

Case Reports in Medicine, Volume 2026, Issue 1, 2026.
Pruritus is a known but uncommon symptom of hyperthyroidism that can be misinterpreted or overlooked in a patient presentation. This is a case report of a 40‐year‐old female who presents with a 3‐month history of severe, worsening pruritus. Further history demonstrated potential signs of hyperthyroidism, and laboratory values demonstrated low TSH ...
Rob Lawless, Evan Smith, Camryn Slone, Thaddeus Salmon, Semonti Nandi   +4 more
wiley   +1 more source

Prospects for targeted therapy of Graves' disease: A review [PDF]

Consilium Medicum
The high prevalence of autoimmune thyroid diseases and the low effectiveness of treatment are the great of the reasons for long-term disability and high disability of patients.
Oksana V. Maksim, Vladimir V. Salukhov, Boris V. Romashevskiy   +2 more
doaj   +1 more source

Exploring Thyrotoxic Hypercalcaemia Through Two Cases: A Myriad of Uncertainties

Case Reports in Endocrinology, Volume 2026, Issue 1, 2026.
Hypercalcaemia is a recognised complication of thyrotoxicosis usually related to increased bone resorption. However, coexistent hyperphosphataemia is uncommon and may create diagnostic uncertainty. It is postulated that serum calcium and phosphate levels rise due to high bone turnover and increased renal reabsorption of phosphate in response to excess ...
Don Asiri Abeysiriwardana, Pahala Gamage Nipuna Jeewantha Dias, Warsha Dilhani De Zoysa, Arosha Sampath Dissanayake, Kalyani Sen   +4 more
wiley   +1 more source

Lugol’s Iodine as a Key Treatment in Transient Gestational Thyrotoxicosis: A Case Report

Case Reports in Endocrinology, Volume 2026, Issue 1, 2026.
Introduction Transient gestational thyrotoxicosis (TGT) occurs when human chorionic gonadotropin (hCG) directly stimulates the maternal thyroid gland during the first trimester of pregnancy. We report a case of complicated TGT in a young woman who required treatment with Lugol’s solution.
Mariam Mabrouk, Najla Bchir, Dorra El Guiche, Anaam Ben Chehida, Emna Mraihi, Chadia Zouaoui, Haroun Ouertani, Mohammad Shahangir Biswas   +7 more
wiley   +1 more source

Unilateral Graves’ Disease Developing During Treatment With Tirzepatide in a Patient With Diabetes: A Case Report

Case Reports in Endocrinology, Volume 2026, Issue 1, 2026.
Background Tirzepatide is a dual agonist of the glucose‐dependent insulinotropic polypeptide (GIP) receptor and glucagon‐like peptide‐1 (GLP‐1) receptor, demonstrates significant efficacy in lowering blood glucose levels and reducing body weight. Consequently, its use has increased among patients with type 2 diabetes and obesity.
Yusuke Deto, Ryo Hasegawa, Shoya Ino, Satoru Shibata, Kouhei Ohno, Takahito Itoh, Tomoaki Matsumoto, Takayuki Miki, Kalyani Sen   +8 more
wiley   +1 more source

Clinical case report: combination of endocrine ophthalmopathy and myasthenia gravis: diagnostic and therapeutic difficulties [PDF]

Клиническая офтальмология
D.S. Atarshchikov1, E.S. Taskina2, D.P. Podkopaeva3, N.I. Kibalina1 1AO GK Medsi, Moscow, Russian Federation 2Chita State Medical Academy, Chita, Russian Federation 3I.M.
D.S. Atarshchikov, E.S. Taskina, D.P. Podkopaeva, N.I. Kibalina   +3 more
doaj  

SEARCH FOR TARGET TISSUE IN THE EYE ORBIT FOR AUTOIMMUNE AGGRESSION OF THYROID ANTIBODIES IN ENDOCRINE OPHTHALMOPATHY

Медицинская иммунология, 2017
We searched for a possible target tissue in eye orbit for thyroid autoantibodies in endocrine ophthalmopathy (Graves’ disease), using correlation analysis method. We examined a group of 139 patients (278 eye orbits) with thyroid-associated ophthalmopathy
V. G. Likhvantseva, M. S. Afanasiev, E. A. Rudenko, A. V. Karaulov, E. V. Korostelyova   +4 more
doaj   +1 more source

Exploring the Therapeutic Mechanism of Xiehuo Pingtu San in Treating Thyroid Eye Disease Based on Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation

International Journal of Endocrinology, Volume 2026, Issue 1, 2026.
Background Xiehuo Pingtu San (XHPTS) has been shown to be safe and effective in treating thyroid eye disease (TED), yet its underlying mechanisms remain unclear. This study aimed to elucidate the active ingredients of XHPTS and their therapeutic mechanisms in TED through network pharmacology, molecular docking, and molecular dynamics simulations ...
Ping Wang, Ruiyan Liu, Xin Shang, Yu Fu, Ying Wang, Shuxun Yan, Suraiya Saleem   +6 more
wiley   +1 more source